Acrivon Therapeutics (ACRV) Common Equity (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Common Equity of $95.5 million for Q1 2026, down 40.45% year-over-year from $160.4 million in Q1 2025, and down 15.11% quarter-over-quarter from $112.5 million in Q4 2025.
Acrivon Therapeutics (ACRV) Common Equity (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Common Equity for 6 consecutive years, with $95.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity fell 40.45% year-over-year to $95.5 million; the TTM figure through Mar 2026 stood at $95.5 million (down 40.45% YoY), while the FY2025 annual figure was $112.5 million, down 36.35% from the prior year.
- Common Equity fell to $95.5 million in Q1 2026 per ACRV's latest filing, from $112.5 million in the prior quarter.
- Across five years, Common Equity topped out at $216.1 million in Q2 2024 and bottomed at -$45.6 million in Q3 2022.
- Historically, Common Equity has averaged $115.5 million across 5 years, with a median of $138.1 million in 2023.
- On a YoY basis, Common Equity climbed as much as 816.01% in 2022 and fell as far as 130.73% in 2022.
- Acrivon Therapeutics' Common Equity stood at $170.5 million in 2022, then fell by 28.91% to $121.2 million in 2023, then jumped by 45.87% to $176.8 million in 2024, then tumbled by 36.35% to $112.5 million in 2025, then fell by 15.11% to $95.5 million in 2026.
- Business Quant data shows ACRV's Common Equity at $95.5 million in Q1 2026, $112.5 million in Q4 2025, and $128.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Acrivon Therapeutics | 92.26 Mn | 92.26 Mn | - | 86.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86.67 Mn |
| Mar 31, 2026 | 95.52 Mn |
| Dec 31, 2025 | 112.52 Mn |
| Sep 30, 2025 | 128.60 Mn |
| Jun 30, 2025 | 143.04 Mn |
| Mar 31, 2025 | 160.39 Mn |
| Dec 31, 2024 | 176.79 Mn |
| Sep 30, 2024 | 196.89 Mn |
| Jun 30, 2024 | 216.06 Mn |
| Mar 31, 2024 | 107.98 Mn |
| Dec 31, 2023 | 121.20 Mn |
| Sep 30, 2023 | 138.15 Mn |
| Jun 30, 2023 | 149.18 Mn |
| Mar 31, 2023 | 160.47 Mn |
| Dec 31, 2022 | 170.48 Mn |
| Sep 30, 2022 | -45.62 Mn |
| Jun 30, 2022 | -36.58 Mn |
| Mar 31, 2022 | -30.99 Mn |
| Dec 31, 2021 | -23.81 Mn |
| Sep 30, 2021 | -19.77 Mn |